Peptide cancer vaccine with STING agonist polymers achieves tumor remission in combination with checkpoint immunotherapy
VIPER endosomolytic peptide vaccine combined with two structurally distinct STING agonist drugamers induced potent anti-tumor CD8+ T cell responses and achieved tumor remission with anti-PD-1 in melanoma and colon cancer mouse models.
Quick Facts
What This Study Found
Both VIPER-STING drugamers enhanced DC maturation and CD8+ T cell responses. polySTING: more tumor-infiltrating CD8+ T cells. NPSTING: more LN antigen-presenting DCs. Both: efficacy in B16-OVA melanoma and MC38 colon cancer. Combination with anti-PD-1: tumor remission + immunity in subset.
Key Numbers
How They Did This
Peptide vaccine platform (VIPER) with 2 STING drugamer structures. B16-OVA melanoma and MC38 colon cancer mouse models. DC maturation, CD8+ T cell assays, combination with anti-PD-1.
Why This Research Matters
Peptide cancer vaccines have struggled in clinical translation due to poor immunogenicity. This platform solves two key problems: endosomal escape (VIPER) and innate immune activation (STING drugamers), achieving the elusive goal of peptide vaccine-mediated tumor remission.
The Bigger Picture
Combining peptide antigen delivery with innate immune stimulation through engineered polymers could finally make peptide cancer vaccines clinically viable—a decades-long goal in immunotherapy.
What This Study Doesn't Tell Us
Mouse models only. Remission in subset of mice (not all). STING agonists can cause systemic toxicity. Manufacturing complexity of polymer-peptide-drugamer system. Human translation uncertain.
Questions This Raises
- ?Which drugamer design (polySTING vs NPSTING) is better for human translation?
- ?Can this platform be adapted for personalized neoantigen vaccines?
- ?Will STING drugamer toxicity be manageable in patients?
Trust & Context
- Key Stat:
- Tumor remission achieved Peptide vaccine + STING drugamers + anti-PD-1 achieved tumor remission and protective immunity in a subset of mice—a breakthrough for peptide vaccine technology
- Evidence Grade:
- Preclinical with multiple cancer models and mechanistic analysis. Strong proof of concept for the platform.
- Study Age:
- Published in 2025.
- Original Title:
- Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.
- Published In:
- Proceedings of the National Academy of Sciences of the United States of America, 122(45), e2409978122 (2025)
- Authors:
- Song, Kefan(2), Nguyen, Dinh Chuong, Wang, Yonghui(2), Jokonya, Simbarashe, Yazdani, Omeed, Sellers, Drew L, Stayton, Patrick S, Pun, Suzie H
- Database ID:
- RPEP-13648
Evidence Hierarchy
Frequently Asked Questions
What is a peptide cancer vaccine?
Peptide cancer vaccines use small pieces of proteins found on cancer cells to train the immune system to recognize and attack tumors. They are safe and easy to manufacture but have historically been too weak to fight cancer alone. This study overcomes that weakness using advanced delivery technology and immune stimulants.
How does this vaccine work?
It uses three components: (1) cancer peptide antigens to identify the target, (2) VIPER polymers that help the vaccine escape cell compartments to reach the immune recognition machinery, and (3) STING drugamers that strongly activate innate immunity. Together with checkpoint immunotherapy, this triple approach achieved tumor remission in mice.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13648APA
Song, Kefan; Nguyen, Dinh Chuong; Wang, Yonghui; Jokonya, Simbarashe; Yazdani, Omeed; Sellers, Drew L; Stayton, Patrick S; Pun, Suzie H. (2025). Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.. Proceedings of the National Academy of Sciences of the United States of America, 122(45), e2409978122. https://doi.org/10.1073/pnas.2409978122
MLA
Song, Kefan, et al. "Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.." Proceedings of the National Academy of Sciences of the United States of America, 2025. https://doi.org/10.1073/pnas.2409978122
RethinkPeptides
RethinkPeptides Research Database. "Peptide vaccine formulations with structurally distinct STIN..." RPEP-13648. Retrieved from https://rethinkpeptides.com/research/song-2025-peptide-vaccine-formulations-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.